MARKET

GRFS

GRFS

Grifols
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.94
+0.25
+1.34%
After Hours: 18.94 0 0.00% 16:00 05/18 EDT
OPEN
18.78
PREV CLOSE
18.69
HIGH
19.05
LOW
18.60
VOLUME
473.02K
TURNOVER
--
52 WEEK HIGH
20.98
52 WEEK LOW
14.81
MARKET CAP
4.95B
P/E (TTM)
18.37
1D
5D
1M
3M
1Y
5Y
Susquehanna International Securities, Ltd. ...
GuruFocus News · 10h ago
Hengistbury Investment Partners LLP Buys Coca-Cola Europacific Partners PLC, Altice USA Inc, ...
GuruFocus News · 1d ago
Nucleic Acid Amplification Testing (NAAT) Market Size, Share, Growth Revenue and Key Company's Profiles, Forecast To 2025
Japan, Japan, Tue, 11 May 2021 01:40:04 / Comserve Inc. / -- The report analyze market size, share, growth, trends, segmentation, top key players,...
Comserve · 05/11 05:42
Tularaemia Treatment Market Growth, Share 2021: Impact of Covid-19, Key Driving Factors, Market Scenario and Forecast 2027
May 07, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The Global "Tularaemia Treatment Market"...
The Express Wire · 05/07 08:14
Black Creek Investment Management Inc. Buys Booz Allen Hamilton Holding Corp, Oracle Corp, The ...
GuruFocus News · 05/06 16:38
Avascular Necrosis Market – Drivers, Restraints, Opportunities and Challenges by Leading Players Bone Therapeutics, Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon Inc., Eli Lilly and Company, Grifols SA
May 06, 2021 (Market Insight Reports) -- Avascular necrosis (AVN) is also referred to as osteonecrosis, or aseptic necrosis, or ischemic bone necrosis. It is...
Market Insight Reports · 05/06 10:47
Analysts Conflicted on These Healthcare Names: Grifols SA (GRFS) and Genfit SA (GNFT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Grifols SA (GRFS) and Genfit SA (GNFT). Grifols SA (GRFS) Kepler Capital
SmarterAnalyst · 05/06 02:05
Nucleic Acid Amplification Testing (NAAT) Market 2021 Highlights Recent Trends, Market Growth and Business Opportunities till 2025 – Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Inc., Grifols SA, Hoffmann-La Roche Ltd, Hologic, Inc.
Market Insight Reports · 05/05 11:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GRFS. Analyze the recent business situations of Grifols through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GRFS stock price target is 27.65 with a high estimate of 35.56 and a low estimate of 19.75.
EPS
Institutional Holdings
Institutions: 275
Institutional Holdings: 107.32M
% Owned: 41.05%
Shares Outstanding: 261.43M
TypeInstitutionsShares
Increased
59
10.61M
New
19
3.54M
Decreased
53
6.92M
Sold Out
34
8.67M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.07%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Non-Executive Chairman
Victor Grifols Roura
Co-Chief Executive Officer/Executive Director
Victor Grifols Deu
Co-Chief Executive Officer/Executive Director
Raimon Grifols Roura
Non-Executive Vice Chairman
Thomas Daga Glanzmann
Non-Executive Vice Chairman
Thomas Glanzmann
Chief Financial Officer
Alfredo Arroyo Guerra
Corporate Executive
PETER ALLEN
Corporate Executive
Joel Abelson
Corporate Executive
Albert Coma-Cros
Corporate Executive
Alberto Grifols Roura
Corporate Executive
Albert Grifols Roura
Corporate Executive
Chris Healey
Corporate Executive
Miguel Pascual Montblanch
Chief Human Resource Officer
Mateo Borras Humbert
Corporate Executive
ROBERT JAGT
Chief Technology Officer
Javier Sueiras Gil
Vice President
Vicente Blanquer Torre
Vice President
Matt Murawski
Vice President
Nuria Pascual Lapena
Vice President
Maria Rione
General Counsel
David Bell
Managing Director
Luis Twose Garcon
Other
Daniel Fleta Coit
Other
Lafmin Morgan
Vice President
Teresa Rione
Secretary
Nuria Martin Barnes
Assistant Secretary/Director
Tomas Daga Gelabert
Lead Director/Independent Director
Inigo Sanchez Asiain Mardones
Other
Daniel Fleta
Director
Ramon Riera Roca
Independent Director
James Costos
Independent Director
Marla Elizabeth Salmon
Independent Director
Enriqueta Felip Font
Independent Director
Steven Mayer
Independent Director
Carina Szpilka Lazaro
Independent Director
Belen Villalonga Morenes
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.143166
10/30/2020
10/31/2019
Dividend USD 0.169716
12/02/2019
05/29/2019
Dividend USD 0.175638
06/07/2019
11/07/2018
Dividend USD 0.22789
11/30/2018
05/25/2018
Dividend USD 0.250975
06/01/2018
--
Dividend USD 0.212979
12/01/2017
--
Dividend USD 0.163528
05/30/2017
--
Dividend USD 0.193644
12/05/2016
--
Dividend USD 0.162059
06/02/2016
--
Dividend USD 0.384765
12/10/2015
--
Dividend USD 0.341846
06/08/2015
--
Dividend USD 0.312792
12/04/2014
05/30/2014
Dividend USD 0.286887
06/05/2014
05/24/2013
Dividend USD 0.258668
06/05/2013
05/17/2013
Dividend USD 0.01283
05/29/2013
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers kinds of Grifols SA - ADR stock information, including NASDAQ:GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.